These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 28626220)
21. A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Justice G; Kessler JF; Jadeja J; Campos L; Weick J; Chen CF; Heatherington AC; Amado RG Ann Oncol; 2005 Jul; 16(7):1192-8. PubMed ID: 15860486 [TBL] [Abstract][Full Text] [Related]
22. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171 [TBL] [Abstract][Full Text] [Related]
23. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813 [TBL] [Abstract][Full Text] [Related]
25. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Hedenus M; Adriansson M; San Miguel J; Kramer MH; Schipperus MR; Juvonen E; Taylor K; Belch A; Altés A; Martinelli G; Watson D; Matcham J; Rossi G; Littlewood TJ; Br J Haematol; 2003 Aug; 122(3):394-403. PubMed ID: 12877666 [TBL] [Abstract][Full Text] [Related]
27. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Toto R; Petersen J; Berns JS; Lewis EF; Tran Q; Weir MR J Am Soc Nephrol; 2021 Feb; 32(2):469-478. PubMed ID: 33288629 [TBL] [Abstract][Full Text] [Related]
28. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Oliva EN; Nobile F; Alimena G; Specchia G; Danova M; Rovati B; Ronco F; Impera S; Risitano A; Alati C; Breccia M; Carmosino I; Vincelli I; Latagliata R Leuk Lymphoma; 2010 Jun; 51(6):1007-14. PubMed ID: 20367566 [TBL] [Abstract][Full Text] [Related]
29. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification. Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362 [TBL] [Abstract][Full Text] [Related]
30. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232 [TBL] [Abstract][Full Text] [Related]
31. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
32. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Vansteenkiste J; Tomita D; Rossi G; Pirker R Support Care Cancer; 2004 Apr; 12(4):253-62. PubMed ID: 14740283 [TBL] [Abstract][Full Text] [Related]
33. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429 [TBL] [Abstract][Full Text] [Related]
34. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445 [TBL] [Abstract][Full Text] [Related]
35. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531 [TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289 [TBL] [Abstract][Full Text] [Related]
37. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149 [TBL] [Abstract][Full Text] [Related]
38. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P; Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Case AS; Rocconi RP; Kilgore LC; Barnes MN Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064 [TBL] [Abstract][Full Text] [Related]
40. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. Voils SA; Harpe SH; Brophy GM Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]